Br J Ophthalmol 95:1476-1477 doi:10.1136/bjophthalmol-2011-300316
  • PostScript
  • Letter

Treatments for macular degeneration: summarising evidence using network meta-analysis

  1. Andrea Messori
  1. Laboratorio SIFO di Farmacoeconomia, Area Vasta Centro Toscana, ESTAV, Prato, Italy
  1. Correspondence to Dr Andrea Messori, Laboratorio SIFO di Farmacoeconomia, c/o Area Vasta Centro Toscana, Regional Health System, Via Guimaraes 9-11, 59100 Prato, Italy;{at}
  1. Contributors All authors contributed equally to this manuscript.

  • Accepted 18 May 2011
  • Published Online First 16 June 2011

In studying treatments for age-related macular degeneration (AMD), randomised controlled trials have typically used placebo or verteporfin in the control group.1 2 Hence, information on direct head-to-head comparisons between the newest agents is still needed.

Network meta-analysis (NMA) is a tool that summarises the information on comparative effectiveness when three or more treatments are proposed for the same clinical indication.3 4 NMA includes both direct comparisons (based on real trials) and indirect comparisons (based on statistical testing in the absence of a real head-to-head trial). The main advantage of NMA lies in its communicative value5; another advantage is that it overcomes one …

Register for free content

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article